Dossier - Page 1 - FirstWord Reports

Learn More The Future of Biosimilars in Europe: Mapping critical uncertainties and the impact of future events

Education is top priority as biosimilar mAbs enter the market With the recent approval of Celltrion’s Truxima, all eyes are on biosimilar oncology monoclonal antibodies (mAbs). Experts say they’re the next...

Compare
Learn More Biomarkers and Companion Diagnostics - Payer views

Winning Payer Support for Companion Diagnostics & Biomakers How can you positively influence payer attitudes to biomarkers and companion diagnostics (CDx)? Biomarkers and CDx are critical to realising the...

Compare
Learn More Charting MSL Activity and Performance (2017)

A unique survey-based report providing key insights and actionable intelligence about MSL activity and performance. Charting MSL Activity and Performance (2017) distils key findings from one of the most comprehensive...

Compare
Learn More Real World Data: Meeting Payer Needs

How to adjust your Real World Data provision to address the real needs of payers Drug costs are spiralling upwards and so too are frustration levels. Payers with stretched budgets are still struggling to make the case...

Compare
Learn More How Payers Want to Work With Pharma

How to effectively engage US and EU payers You’re speaking to payers, but are they listening? Do you really understand their needs and concerns? Is your approach to payer negotiations getting your...

Compare
Learn More Medical Affairs in Orphan Drugs

Orphan drugs: Is your medical affairs team leading the fray or lagging behind? Traditional commercial models simply don’t work for orphan drugs, not least because the physician and patient populations are so...

Compare
Learn More Pulling the Data Puzzle Together: Being Payer-Centric

Mapping data with payer needs. How to solve the data puzzle. Everyone is talking about data. What’s being collected; how robust is it; what does it prove; who should be told? From the all-important payer...

Compare
Learn More Charting the Orphan Drug Development Pipeline

Which are the most exciting areas of orphan drug research and where are the best opportunities? Global sales of drugs for orphan indications were estimated to be $114 billion in 2016, with sales forecast to rise to $209...

Compare
Learn More Biosimilars in Emerging Markets (2017)

Biosimilars: Make the most of high risk emerging market opportunities Emerging biosimilars markets are currently a $5billion opportunity with even more growth potential ahead. Lower drug costs and improved patient...

Compare
Learn More Biosimilars: US Payer Perspectives (2017)

Will biosimilar provide a ‘magic bullet’ to drug prices in the US? Payers speak out… Biosimilars continue to be big business in the US, but has progress has been too slow? Not so, argue payers...

Compare
Learn More The Future of Biobetters

Strategies for success in the biobetter market How can you successfully position biobetter products in the increasingly crowded branded biologic/biosimilar space? With the prospect of improving patient adherence,...

Compare
Learn More Real World Data Capabilities: Benchmarking Pharma Companies

Is Real World Data giving your market access the power charge it needs? Real World Data (RWD) and Real World Evidence (RWE) are gaining traction across the industry. The front runners are already exploring new ways to...

Compare
Learn More Overcoming Market Access Barriers to High Value Drugs

Overcoming market access barriers to high-value drugs How can you breakthrough the market access barriers that face high-value oncology and immunotherapy products in the EU5 and US? Pharma faces unprecedented demands...

Compare
Learn More Biosimilars: European Payer Perspectives (2017)

What is the future for biosimilars in the EU? What issues do EU Payers think will impact adoption, pricing and reimbursement of biosimilars? In January 2016 Samsung Bioepis launched Benepali, a biosimilar version of...

Compare
Learn More The Future of Medical Affairs

What are the future opportunities and challenges for medical affairs? As the interface between companies and KOLs, HCPs, payers and patients, medical affairs has grown rapidly in importance. And demands are set to...

Compare
Learn More Defending Against Biosimilars: Originator strategies

Battle of the biologics: How to survive The onward march of biologics has shaped a brave new world for drug manufacturers with conflicting rules and regulations and an eclectic mix of individual players to contend with...

Compare
Learn More Value Added Services: Payer Perspectives (2016)

Payer viewpoint: What should value-added services be providing? Getting close to payers and finding out exactly what they want from value-added services (VAS) has proved problematic for the pharmaceutical...

Compare
Learn More Biosimilars Education: Addressing a significant unmet need

How to educate stakeholders about biosimilar benefits What information and data do physicians, payers and patients need about biosimilars? As the market expands and new therapeutic sectors come on stream, more...

Compare
Learn More KAM Metrics: Measuring Success

Do you have the right metrics in place to know how well your KAM team is performing? A Key Account Management (KAM) approach has taken hold in pharma circles, but is it producing results? Plenty of resources have been...

Compare
Learn More Market Access and Commercial Excellence in Managed Markets

Commercial strategies for successful US managed market access Employ effective commercial strategies for optimal formulary position, pricing and reimbursement in US managed care markets. Healthcare reforms,...

Compare

Browse by